LY96 and malignant colon neoplasm: Selective targeting of the TLR4 co-receptor, MD2, using the inhibitor L6H21, has been shown to suppress colon cancer growth and metastasis by blocking the TLR4-MD2/NF-κB signaling pathway [76].